Head to Head Comparison: Indivior (NASDAQ:INDV) versus Contineum Therapeutics (NASDAQ:CTNM)

Indivior (NASDAQ:INDV) and Contineum Therapeutics (NASDAQ:CTNM) are both healthcare companies, but which is the better business? We will contrast the two companies based on the strength of their institutional ownership, earnings, valuation, profitability, dividends, risk and analyst recommendations.

Analyst Ratings

This is a breakdown of recent recommendations and price targets for Indivior and Contineum Therapeutics, as provided by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Indivior	0	2	5	0	2.71
Contineum Therapeutics	1	1	4	0	2.50

Indivior presently has a consensus price target of $45.17, indicating a potential upside of 27.66%. Contineum Therapeutics has a consensus price target of $22.17, indicating a potential upside of 70.64%. Given Contineum Therapeutics’ higher possible upside, analysts clearly believe Contineum Therapeutics is more favorable than Indivior.

Institutional & Insider Ownership

60.3% of Indivior shares are held by institutional investors. 0.7% of Indivior shares are held by insiders. Comparatively, 7.9% of Contineum Therapeutics shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Valuation and Earnings

This table compares Indivior and Contineum Therapeutics”s gross revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Indivior	$1.24 billion	3.37	$210.00 million	$2.79	12.68
Contineum Therapeutics	$50.00 million	9.77	-$59.98 million	($1.73)	-7.51

Indivior has higher revenue and earnings than Contineum Therapeutics. Contineum Therapeutics is trading at a lower price-to-earnings ratio than Indivior, indicating that it is currently the more affordable of the two stocks.

Volatility & Risk

Indivior has a beta of 0.87, indicating that its share price is 13% less volatile than the S&P 500. Comparatively, Contineum Therapeutics has a beta of 0.86, indicating that its share price is 14% less volatile than the S&P 500.

Profitability

This table compares Indivior and Contineum Therapeutics’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Indivior	26.65%	-283.11%	36.85%
Contineum Therapeutics	N/A	-24.73%	-23.51%

Summary

Indivior beats Contineum Therapeutics on 10 of the 14 factors compared between the two stocks.

About Indivior

Indivior PLC, together with its subsidiaries, engages in the development, manufacture, and sale of buprenorphine-based prescription drugs for the treatment of opioid dependence and co-occurring disorders in the United States, the United Kingdom, and internationally. The company develops medicines to treat substance use disorders, serious mental illnesses, and opioid overdose. Its core marketed products include SUBLOCADE and SUBUTEX PRO buprenorphine extended-release monthly injections; SUBOXONE, a buprenorphine and naloxone sublingual film; SUBOXONE, a buprenorphine and naloxone sublingual tablet; and SUBUTEX, a buprenorphine sublingual tablet for the treatment of opioid use disorder. The company also offers OPVEE nasal spray for opioid overdose reversal; and PERSERIS extended-release injectable suspension for the treatment of schizophrenia in adults. In addition, it is developing INDV-2000, a selective orexin-1 receptor antagonist that completed phase 1 clinical trial for the treatment of opioid use disorder (OUD); INDV-1000, a selective GABAb positive allosteric modulator, which is in pre-clinical development phase for the treatment of alcohol use disorder in collaboration with ADDEX therapeutics; INDV-6001, a buprenorphine-based long-acting injectable for the treatment of OUD in collaboration with Alar Pharmaceuticals Inc.; and CT-102, a digital therapeutic for the treatment of OUD in collaboration with Click Therapeutics. Further, the company is developing INDV-5004, a drinabant injection to treat acute cannabinoid overdose. It has a strategic partnership with Aelis Farma to develop AEF0117, a synthetic CB1 specific signaling inhibitor that is in phase 2B clinical trial for the treatment of cannabis use disorder. The company was incorporated in 2014 and is headquartered in North Chesterfield, Virginia.

About Contineum Therapeutics

Contineum Therapeutics, Inc., a clinical stage biopharmaceutical company, focuses on discovering and developing novel oral small molecule therapies for neuroscience, inflammation, and immunology indications with high unmet need. Its lead asset is PIPE-791, a novel, brain penetrant, small molecule inhibitor of the lysophosphatidic acid 1 receptor (LPA1R) for the treatment of idiopathic pulmonary fibrosis and progressive multiple sclerosis (MS). The company also develops PIPE-307, a novel, small molecule selective inhibitor of the muscarinic type 1 M1 receptor to treat depression and relapse remitting MS; and CTX-343, a peripherally-restricted LPA1R antagonist. Contineum Therapeutics, Inc. was formerly known as Pipeline Therapeutics, Inc. and changed its name to Contineum Therapeutics, Inc. in November 2023. The company was incorporated in 2009 and is headquartered in San Diego, California.